Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

7.910 -0.460 (-5.50%)
Streaming Delayed Price Updated: 12:37 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 Next >
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
Event to feature KOL perspective on emerging MASH therapies 
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule,
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
November 16 Event to feature KOL perspective on Emerging HBV Therapies 
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces $92 Million Private Placement Financing
From Aligos Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.